Title
A CRISPR-Based Toolbox for Studying T Cell Signal Transduction.

Permalink
https://escholarship.org/uc/item/6684m9c2

Journal
BioMed research international, 2016

ISSN
2314-6133

Authors
Chi, Shen
Weiss, Arthur
Wang, Haopeng

Publication Date
2016

DOI
10.1155/2016/5052369

Peer reviewed
Research Article

A CRISPR-Based Toolbox for Studying T Cell Signal Transduction

Shen Chi,1 Arthur Weiss,2,3 and Haopeng Wang1

1School of Life Science and Technology, ShanghaiTech University, Shanghai 200031, China
2Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143, USA
3Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA

Correspondence should be addressed to Arthur Weiss; aweiss@medicine.ucsf.edu and Haopeng Wang; wanghp@shanghaitech.edu.cn

Received 23 September 2015; Revised 18 December 2015; Accepted 28 December 2015

Academic Editor: Hannes Stockinger

Copyright © 2016 Shen Chi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CRISPR/Cas9 system is a powerful technology to perform genome editing in a variety of cell types. To facilitate the application of Cas9 in mapping T cell signaling pathways, we generated a toolbox for large-scale genetic screens in human Jurkat T cells. The toolbox has three different Jurkat cell lines expressing distinct Cas9 variants, including wild-type Cas9, dCas9-KRAB, and sunCas9. We demonstrated that the toolbox allows us to rapidly disrupt endogenous gene expression at the DNA level and to efficiently repress or activate gene expression at the transcriptional level. The toolbox, in combination with multiple currently existing genome-wide sgRNA libraries, will be useful to systematically investigate T cell signal transduction using both loss-of-function and gain-of-function genetic screens.

1. Introduction

T cells play an essential role in the human immune system and have been identified as mediators of various systemic autoimmune diseases. In the past two decades, the studies of how T cell receptors (TCRs) are stimulated by non-self-antigens and how T cell activation is regulated are central topics in the immunology field [1, 2]. T cell stimulation is triggered by the engagement of the TCR to a cognate peptide-major histocompatibility complex (MHC) on antigen-presenting cells (APCs). Following the formation of a TCR-peptide-MHC complex, two tyrosine residues, which are part of the immunoreceptor tyrosine-based activation motifs (ITAMs) within the short proximal cytoplasmic tails of their TCR-associated CD3 and ζ-chain subunits, are phosphorylated [1]. Such phosphorylation of ITAMs is mediated by the T cell Src-related protein tyrosine kinases (Src-PTKs) such as Lck. Phosphorylated ITAMs further recruit the cytoplasmic kinase ZAP-70 via its tandem Src-homology domains binding to the doubly phosphorylated ITAMs. ZAP-70 subsequently phosphorylates two signaling adaptor proteins, the linker for the activation of T cells (LAT) and the SH2-domain-containing leukocyte protein of 76 kDa (SLP-76). These two molecules function as the scaffolds to recruit many other signaling molecules, which eventually lead to T cell activation [2].

Most of our fundamental knowledge of TCR signaling transduction came from the studies of several human T cell lines, particularly the Jurkat leukaemic T cell line [3]. To investigate how signaling effector proteins mediate T cell activation response, a series of Jurkat mutants were generated by using mutagenesis. For example, J.CaM1 cell line is a Jurkat-derived Lck deficient mutant, which is impaired in T cell signaling [4]. This cell line was generated by sorting mutagenized Jurkat cells, which had a defective Ca2+ mobilization response triggered by TCR stimulation. Using a similar Ca2+ flux based strategy, the P116 cell line, which lacks ZAP-70 expression, was generated and has been widely used in studies of ZAP-70 function [5].

With the development of sequence-specific DNA nuclelease technologies, genome editing is becoming a critical
approach used to analyze biological functions in cell lines and animal models [6]. More recently, clustered regularly interspaced palindromic repeats- (CRISPR-) associated (Cas) protein 9 (known as CRISPR-Cas9) system has been demonstrated to target and induce site-specific DNA double-strand breaks (DSBs) directed by a single-guide RNA (sgRNA) [7]. The DNA repair of DSBs is mediated by either nonhomologous end joining (NHEJ) or homology directed repair (HDR), which can be used to introduce random or specific mutations, repair of endogenous mutations, or insertion of DNA elements [8]. Interestingly, the deactivated Cas9 (dCas9), which results from inactivated nuclease domains in Cas9, is also able to function as a DNA-binding scaffold to either silence (CRISPRi) or activate (CRISPRa) gene expression, depending on the transcription effector domains fused to Cas9 [9–11]. Consequently, the CRISPR-Cas9 system has been widely used to precisely and effectively generate engineered eukaryotic cells [12–14]. Recently, a series of studies performed both loss-of-function and gain-of-function screens in a genome-wide scale in E. coli [15], zebrafish cells [16], and K562 tumor cell lines [17] as well as primary mouse dendritic cells [18]. In addition, several human sgRNA libraries for genome-wide screen have been established [10, 19, 20]. However, to our knowledge, a CRISPR-based genome-wide screen to study T cell activation has not been reported, which might be largely due to a lack of Jurkat cell lines optimized for such screens. Here we developed a toolbox of three Jurkat cell lines, which are engineered for CRISPR, CRISPRi, or CRISPRa screens, respectively. These cell lines were derived from a single cell clone and expressed uniform and normal levels of TCR and CD28 receptors to ensure they could undergo efficient T cell stimulation. We also demonstrated that we could use CRISPR, CRISPRi, and CRISPRa to target endogenous genes and regulate their expression levels in these cell lines. Collectively, this toolbox represents a useful platform for systematically dissecting T cell signaling pathways.

2. Results

The CRISPR-Cas9 system has proven to be a powerful tool to perform individual gene editing and large-scale genetic screens [19] (Figure 1(a)). Recently, the CRISPR/Cas9 system has been used in Jurkat T cells as well as primary human T cells [21–24]. However, to our knowledge, no Cas9-based loss-of-function genetic screen has been reported in human T cells, probably due to the difficulty of expressing functional Cas9 within T cells. To facilitate future genetic screen using human T cells, we sought to generate a Jurkat cell line stably expressing functional WT-Cas9 and optimized for large-scale genetic screens.

We first cloned wild-type Cas9 and a 2A-linked blue fluorescent protein (BFP) reporter gene into a lentiviral construct driven by the spleen focus-forming virus promoter (SFFV). This lentivirus was generated and used to infect Jurkat T cells. After lentiviral transduction, flow cytometry sorting was used to isolate a bulk population of BFP-positive Jurkat cells with normal surface expression amounts of both TCR and CD28 receptors, two major cell surface receptors that contribute to T cell activation. We named this cell population as JXBulk. To test whether WT-Cas9 protein in JXBulk cells had any genome editing function, we designed an sgRNA to specifically target the beta-2 microglobulin (B2M) gene. B2M is a subunit of MHC class I molecules, which are highly expressed in all leukocytes, including human T cells. It has been demonstrated that disruption of B2M gene resulted in ablating MHC class I surface expression [25]. Therefore, the loss of MHC class I expression after expressing sgRNA against B2M served as a functional readout of WT-Cas9 activity in JXBulk cells. We expressed a control sgRNA (sgRNA Control) or an sgRNA targeting B2M gene (sgRNA B2M) in JXBulk cells by electroporation. The sgRNA expressing vector also contains the GFP gene as a reporter. We measured the expression level of surface MHC class I molecules in GFP+ JXBulk cells using FACS analysis. We found that there was little effect on MHC class I expression in the sample expressing sgRNA Control. In contrast, about 40% of JXBulk cells completely lost MHC class I expression 6 days after electroporation of sgRNA B2M (Figure 1(b)). Our kinetic results also indicated that the disruption of MHC class I expression caused by WT-Cas9 mediated gene editing was permanent and irreversible (Figure 1(c)).

To further optimize the efficiency of WT-Cas9, JXBulk cells were single cell sorted and over 48 single cell subclones were further cultured. We compared the efficiency of WT-Cas9 function in these subclones. We found that clone I7 (hereafter referred to as JX17) displayed much higher gene editing efficiency than JXBulk. Our results show that more than 60% of JX17 cells lose their MHC class I expression 6 days after sgRNA B2M electroporation (Figure 1(c)). Therefore, single cell sorting and subcloning are an effective approach to identify cells with optimal Cas9 efficiency. Our results also suggested that it required at least 6 days of cell growth after expression of sgRNA into JX17 cells to permit WT-Cas9 to reach maximal gene editing efficiency in a Cas9-based genetic screen and this should be considered for future genetic screens.

It is reported that wild-type Cas9 is able to cleave off-target sites that have up to five mismatches relative to the guide RNA [26, 27]. To test whether the loss of MHC class I expression we observed in Figure 1(b) was caused by off-target effects of wild-type Cas9 expressed in JX17, we performed a rescue experiment. Briefly, JX17 cells were electroporated with sgRNA B2M as described in Figure 1(b), and we sorted MHC class I-negative JX17 cells, whose endogenous B2M gene was disrupted by electroporation of sgRNA B2M. We then expressed either an empty vector or the human B2M cDNA in these sorted cells by electroporation. 48 hours later, we measured surface expression of MHC class I by flow cytometry (Figure 1(d)). We found that exogenous expression of B2M gene, but not empty vector, increased MHC class I surface expression level, suggesting the loss of MHC class I expression indeed resulted from B2M deficiency.

We next tested whether the effectiveness of WT-Cas9 disruption of the target gene was related to the sgRNA dose. Six days after sgRNA transfection, the transfected JX17 cells
Figure 1: Continued.
were divided into four groups with negative, low, medium, or high expression of GFP, whose expression should be proportional to sgRNA level in cells. The expression of control sgRNA did not affect the surface level of MHC class I. In contrast, there was an sgRNA dose-dependent increase in the percentage of T cells that lost expression of surface MHC class I molecules. We found that an intermediate expression level of sgRNA was sufficient to reach maximal gene editing in JX17 cells (Figure 1(e)). Collectively, these results revealed the potential of JX19 cell line as a useful platform to perform WT-Cas9 mediated genetic screens.

CRISPR interference (CRISPRi) has been demonstrated to be a robust system to turn down gene expression at the transcriptional level with minimal off-target effects [28]. The Krüppel associated box (KRAB) domain, a transcriptional repression domain, is often fused to dCAS9 and used in CRISPRi systems (Figure 2(a)) [29]. In addition to repressing coding RNAs, CRISPRi can also target transcripts including noncoding RNAs and microRNAs [30]. However, a T cell line specifically optimized for the CRISPRi system has not been established. To address this issue, we stably expressed a dCas9-BFP-KRAB fusion protein, which was described previously [10], in Jurkat T cells. We sorted BFP+Jurkat cells expressing dCas9-KRAB (hereafter referred to as JKBulk) with high expression of TCR and CD28 receptors. To test the activity of dCas9-KRAB in JKBulk, we transfected an sgRNA targeting the CD28 gene and measured surface CD28 expression at different time points following transfection (Figures 2(b) and 2(c)). Similar to the WT-Cas9 system, we also used single cell sorting to identify a subclone cell line (JK28) with optimal dCas9-KRAB activity. We observed that about 40% of JKBulk cells and approximately 70% of JK28 cells had reduced CD28 expression amounts 6 days after transfection (Figure 2(b)). Interestingly, unlike the WT-Cas9-based genomic DNA editing, the reduction of CD28 expression was gradually recovered, which might result from the degradation of the CD28 sgRNA as the cells were cultured following transient transfection of the CD28 sgRNA (Figure 2(c)). Our results suggested that stable expression of sgRNA might be needed to maintain dCas9-KRAB mediated gene silencing. Hence, delivery of sgRNA via viral transduction might be a means to achieve long time gene silencing in JK28 cells.

To test whether the sgRNA is a limiting factor for CRISPRi activity, we divided the transfected JK28 cells into four populations with GFP negative, low, medium, or high expression level. We measured surface expression level of CD28 by flow cytometry 6 days following transfection (Figure 2(c)). Figure 2(d) revealed a dose relationship between the sgRNA expression and the percentage of cells with low expression of CD28. Notably, over 80% of cells lose CD28 expression in the population with high GFP expression...
Transcriptional repression

Figure 2: Continued.
level. Thus, robust expression of sgRNA is likely preferable in a CRISPRi based genetic screen.

We next aimed to test whether gene silencing using dCas9-KRAB could induce a functional change of the JK28 cell line. CD28 is a costimulatory receptor that can provide a second signal, when combined with TCR ligands, to induce interleukin 2 (IL-2) production [31]. Blocking CD28 function by using CTLA4-Ig, a CTLA4-immunoglobulin recombinant fusion protein, during Jurkat T cell activation largely inhibited the production of the cytokine IL-2 (Figure 2(e)) [31]. We tested whether transfected sgRNA targeting CD28 in JK28 cells could result in a similar effect. We found that silencing CD28 expression using dCas9-KRAB markedly reduced IL-2 production. In contrast, JK28 cells expressing control sgRNA did not affect the amount of IL-2 production. This result demonstrated that dCas9-KRAB in JK28 cells potently mediated gene silencing that could result in alteration of Jurkat T cell function.

Recently, Tanenbaum et al. developed a sunCas9 system, which could be used to activate gene transcription (CRISPRa) [11]. In this system, multiple copies of the transcriptional activating effector domain (VP64) are recruited to a single dCas9 protein fused with the SunTag. The sgRNA targets the sunCas9 system to the promoter region of an endogenous gene and turns on its transcription (Figure 3(a)). To generate a T cell line with functional sunCas9, Jurkat cell lines were generated to express both dCas9-SunTag-P2A-BFP and GCN4-sfGFP-NLS-VP64, which were described previously [11]. Transduced GFP+BFP+Jurkat cells with high-level expression of TCR and CD28 receptors were single cell sorted and 24 single cell subclones were further cultured. To test the sunCas9 function in transduced cells, these cells were infected with a lentivirus that expressed either an sgRNAcontrol or an sgRNA targeting CXCR4 (sgRNA CXCR4). CXCR4 is a chemokine receptor that is highly expressed in T cells and plays important roles in T cell trafficking and homing. We measured the CXCR4 expression using flow cytometry 6 days after lentivirus infection. Among 24 single cell subclones we screened, one clone (JS19) has the highest activity of sunCas9 system. In JS19 cells, we observed a remarkable upregulation of CXCR4 expression (6-fold) in JS19 cells expressing sgRNA CXCR4 compared to those infected with sgRNAControl virus (Figure 3(b)). CXCR4 is well-expressed in Jurkat cells (Figure 3(b)), so we next tested whether a gene that is normally not expressed in T cells could be induced using JS19 cell line. To this end, we chose the platelet-derived growth factor receptor (PDGFR), which is a cell surface tyrosine kinase growth factor receptor for members of the platelet-derived growth factor family [32]. Jurkat cells normally are negative for PDGFR expression [33]. Consistent with this, we detected little expression of PDGFRB in JS19 cells expressing sgRNAControl. In contrast, transduction of sgRNA targeting PDGFRB substantially enhanced PDGFR expression level in JS19 cells. Taken together, these results showed that sunCas9 system in JS19 robustly increased the transcription of an endogenous gene and could be a
useful platform to perform a gain-of-function genetic screen in human T cell lines.

3. Discussion

Systematic investigation of a signaling pathway depends on the ability to manipulate potential effector genes involved within this pathway through deletion, suppression, or over-expression. To study T cell signaling transduction, we developed a toolbox including three human T cell lines, JX17, JK28, and JS19. Using this toolkit, it should be possible to perform both loss-of-function and gain-of-function genetic screens in the Jurkat-derived human T cell lines. To help researchers determine which cell line they should use in their future screens, we compared these three cell lines based on our results as well as previous studies [6, 10] and summarized results in Table I.

Notably, our toolkit has the following unique advantages. First, these three cell lines were sorted to ensure they expressed high level of the TCR and CD28. Therefore, these cell lines could undergo efficient T cell activation; for example, JK28 was able to produce a substantial amount of IL-2 after T cell activation (Figure 2(e)). Second, all three cell lines are derived from the same population of Jurkat cells maintained in our lab. Though expressing different Cas9 variants, there is minimal internal variation among these cell lines. Thus, the results generated from different genetic screens can be compared in a similar context. Lastly, we should be able to combine multiple genetic screens using this toolbox to address the same biological question at the same time. For example, two independent loss-of-function screens, one using JX17 cells expressing WT-Cas9 and the other using JK28 cells expressing dCas9-KRAB, could be performed side by side. We would expect to identify the candidate genes with high confidence. On the other hand, researchers will be able to use JK28 cells (CRISPRi) and JS19 cells (CRISPRa) to screen for both loss-of-function and gain-of-function phenotypes in the same biological assay. These two screen results should complement each other to provide a rich and comprehensive understanding of T cell signaling.

In sum, we believe that our toolbox will be a useful platform to study T cell function. The programmability of Cas9 and extensive protein engineering of Cas9 will lead to the development of more Cas9 variants with novel functions. We expect to further increase family members in our toolbox in the future.

4. Experimental Procedures

4.1. Cell Culture and Reagent. Jurkat cells were grown in RPMI-1640 containing 5% FCS/Pen/Strep. Anti-HLA-PE-Cy7 (clone: G46-2.6), anti-CXCR4-APC (clone: 12G5), and
Table 1: Comparisons between JX17, JK28, and JS19.

|                      | JX17                     | JK28                     | JS19                     |
|----------------------|--------------------------|--------------------------|--------------------------|
| Genetic screen type  | Loss-of-function         | Loss-of-function         | Gain-of-function         |
| Mechanism            | Frame shift genome mutation | Transcriptional repression | Transcriptional activation |
| Regulation           | Permanent                | Reversible               | Reversible*              |
| Target region        | Gene*                    | Gene, microRNA, and lincRNA* | Gene, microRNA, and lincRNA* |
| Efficiency           | >70%                     | >80%                     | 3–6-fold                 |
| sgRNA expression time required | >5 days                  | >6 days                  | A week                   |
| Available genome-wide libraries | Ref. [19, 20]          | Ref. [10]                | Ref. [10]                |

*Based on [6].

anti-PDGFRB (clone: REA363) were purchased from BD, Biolegend and Miltenyi Biotech, respectively.

4.2. sgRNA Sequence Selection. For sgRNA B2M, we manually chose a 20 nt guide sequence preceding the 5'-NGG PAM, which contains the ATG start codon of B2M gene. For the sgRNA used in CRISPRi system, we followed the rule that the sgRNA should be located within a region from −50 to +300 bp relative to the transcriptional starting site (TSS) [34]. Since the TSS site of the human CD28 gene was previously mapped to between +1 and +61 of the 1st exon [35] and ATG start codon located at +223, we chose an sgRNA sequence around the ATG start codon for the convenience. For sgRNA CXCR4, we used an sgRNA sequence that was validated in the previous study [11]. The sgRNA PDGFRB and sgRNA Control were generously provided by Dr. Boettcher at UCSF from an sgRNA library (unpublished data). The following sgRNAs were used:

- sgRNA Control: GTAGAACGAGCCAACCATTT,
- sgRNA B2M: GGCCGAGATGTCTCGCTCCG,
- sgRNA CD28: GAGCATCTTTCTCCTGACGA,
- sgRNA CXCR4: GCAGACGCGAGGAAGGAGGC-GC,
- sgRNA PDGFRB: ATCCTGAGCGAACGGGCGAT.

4.3. Generation of Jurkat Cells Stably Expressing Cas9 Variants. We fused the WT-Cas9 that was flanked by two nuclear localization sequences (NLS) with T2A-BFP and inserted this cassette into a lentivirus vector under SFFV promoter. The dCas9-KRAB and dCas9-SunTag as well as scFV-sfGFP-VP64 constructs were described previously [10, 11]. Lentivirus expressing Cas9 variants was generated using 293FT cells. The WT Jurkat T cells were expanded in the medium containing the virus for a week and these cells were harvested and stained with anti-CD28 (Tonbo, clone: CD28.2) and anti-CD3 (Tonbo, clone: UCHT1). The BFP+CD28+CD3+ Jurkat cells were then isolated using flow cytometry for further culture. For the sunCas9 system, Jurkat cells were transduced with both dCas9-SunTag virus and scFV-sfGFP-VP64 virus. One week after transduction, BFP+sGFP+CD28+CD3+ Jurkat cells were sorted. Upon request, all of the three cell lines (JX17, JK28, and JK19) are available from Dr. Haopeng Wang’s lab at ShanghaiTech University (wanghp@shanghaitech.edu.cn).

4.4. Expression of sgRNA in Jurkat Cells by Electroporation or Lentiviral Transduction. The sgRNAs were cloned into pLKO.1-GFP vector (a gift from Dr. Shen from NIBS) [36]. To facilitate FACS-based stable clone selection, the original pLKO.1-puro plasmid (Addgene# 8433) was modified. Briefly, EGFP was cloned into the original pLKO vector to replace the puRO sequence using BamHI and KpnI, and then DNA sequence containing gRNA scaffold was cloned into a site following the U6 promoter using NdeI and EcoRI. sgRNA sequence was inserted into the pLKO1-GFP vector by using the BfuAI site. This vector is available upon request by sending an email to Dr. Xiaodong Wang (wangxiaodong@nibs.ac.cn) or Dr. Zhirong Shen (shenzhirong@nibs.ac.cn). Jurkat cells were transfected with these sgRNA plasmids using electroporation according to the preset protocol in Genepulser (Bio-Rad). At different time points after transfection, Jurkat cells were harvested and analyzed by using BD Fortessa flow cytometer. For the sunCas9 system, JS19 cells were infected with lentivirus encoding the sgRNA. Transduced cells were cultured for a week. Measurements of surface CXCR4 level were performed by FACS.

4.5. IL-2 Assay. Jurkat T cells were stimulated by super-antigen SEE presented by Raji B cells in the presence or the absence of CTLA4-Ig as described [31]. After 22 hours, the supernatants were collected and IL-2 production was measured by using Human IL-2 ELISA Kit (BD Biosciences) according to the manufacturer’s instructions.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Marianne Mollenauer for excellent technical assistance; R. Locksley and Z. Wang (UCSF) for access and assistance with cell sorting; Z. Shen (National Institute
of Biological Sciences) for providing pLKO.1; M. Tanenbaum (UCSF) for providing sunCas9 system plasmid; M. Boettcher (UCSF) for providing dCas9-KRAB virus as well as sgRNA\textsuperscript{Control} and sgRNA\textsuperscript{PDGFRB} sequences; C. Liu and W. Shang (ShanghaiTech University) for critical reading of and comments on the paper. This work was supported by a postdoctoral training grant from the Arthritis Foundation (Haopeng Wang) and an NIH T32 training grant (Haopeng Wang) as well as the Howard Hughes Medical Institute (Arthur Weiss).

References

[1] A. K. Chakraborty and A. Weiss, “Insights into the initiation of TCR signaling,” Nature Immunology, vol. 15, no. 9, pp. 798–807, 2014.
[2] H. Wang, T. A. Kadlecek, B. B. Au-Yeung et al., “ZAP-70: an essential kinase in T-cell signaling,” Cold Spring Harbor perspectives in biology, vol. 2, no. 5, Article ID a002279, 2010.
[3] R. T. Abraham and A. Weiss, “Jurkat T cells and development of the T-cell receptor signalling paradigm,” Nature Reviews Immunology, vol. 4, no. 4, pp. 301–308, 2004.
[4] M. A. Goldsmith and A. Weiss, “Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 19, pp. 6879–6883, 1987.
[5] B. L. Williams, K. L. Schreiber, W. Zhang et al., “Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line,” Molecular and Cellular Biology, vol. 18, no. 3, pp. 1388–1399, 1998.
[6] M. Boettcher and M. T. McManus, “Choosing the right tool for the job: RNAi, TALEN, or CRISPR,” Molecular Cell, vol. 58, no. 4, pp. 575–585, 2015.
[7] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science, vol. 337, no. 6096, pp. 816–821, 2012.
[8] J. A. Doudna and E. Charpentier, “The new frontier of genome engineering with CRISPR-Cas9,” Science, vol. 346, no. 6213, 2014.
[9] L. A. Gilbert, M. H. Larson, L. Morsut et al., “CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes,” Cell, vol. 154, no. 2, pp. 442–451, 2013.
[10] L. A. Gilbert, M. A. Horlbeck, B. Adamson et al., “Genome-scale CRISPR-mediated control of gene repression and activation,” Cell, vol. 159, no. 3, pp. 647–661, 2014.
[11] M. E. Tanenbaum, L. A. Gilbert, L. S. Qi, J. S. Weissman, and R. D. Vale, “A protein-tagging system for signal amplification in gene expression and fluorescence imaging,” Cell, vol. 159, no. 3, pp. 635–646, 2014.
[12] F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, and F. Zhang, “Genome engineering using the CRISPR-Cas9 system,” Nature Protocols, vol. 8, no. 11, pp. 2281–2308, 2013.
[13] P. D. Hsu, E. S. Lander, and F. Zhang, “Development and applications of CRISPR-Cas9 for genome engineering,” Cell, vol. 157, no. 6, pp. 1262–1278, 2014.
[14] J. G. Zalatan, M. E. Lee, R. Almeida et al., “Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds,” Cell, vol. 160, no. 1-2, pp. 339–350, 2015.
[15] D. Bikard, W. Jiang, P. Samai, A. Hochschild, F. Zhang, and L. A. Marraffini, “Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system,” Nucleic Acids Research, vol. 41, no. 15, pp. 7429–7437, 2013.
[16] L.-E. Jao, S. R. Wente, and W. Chen, “Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 34, pp. 13904–13909, 2013.
[17] P. Mali, L. Yang, K. M. Esvelt et al., “RNA-guided human genome engineering via Cas9,” Science, vol. 339, no. 6121, pp. 823–826, 2013.
[18] O. Parnas, M. Jovanovic, T. M. Eisenhaure et al., “A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks,” Cell, vol. 162, no. 3, pp. 675–686, 2015.
[19] O. Shalem, N. E. Sanjana, E. Hartenian et al., “Genome-scale CRISPR-Cas9 knockout screening in human cells,” Science, vol. 343, no. 6166, pp. 84–87, 2014.
[20] T. Wang, J. J. Wei, D. M. Sabatini, and E. S. Lander, “Genetic screens in human cells using the CRISPR-Cas9 system,” Science, vol. 343, no. 6166, pp. 80–84, 2014.
[21] X. Liang, J. Potter, S. Kumar et al., “Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection,” Journal of Biotechnology, vol. 208, pp. 44–53, 2015.
[22] A. Hendel, R. O. Bak, J. T.Clark et al., “Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells,” Nature Biotechnology, vol. 33, no. 9, pp. 985–989, 2015.
[23] K. Schumann, S. Lin, E. Boyer et al., “Generation of knock-in primary human T cells using Cas9 ribonucleoproteins,” Proceedings of the National Academy of Sciences, vol. 112, no. 33, pp. 10437–10442, 2015.
[24] C. Li, G. E. Griffin, Y. Liu et al., “Inhibition of HIV-1 infection of primary CD4\textsuperscript+ T-cells by gene editing of CCR5 using adeno-virus-delivered CRISPR/Cas9,” Journal of General Virology, vol. 96, no. 8, pp. 2381–2393, 2015.
[25] L. Riobolos, R. K. Hirata, C. J. Turtel et al., “HLA engineering of human pluripotent stem cells,” Molecular Therapy, vol. 21, no. 6, pp. 1232–1241, 2013.
[26] Y. Fu, J. A. Foden, C. Khayter et al., “High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells,” Nature Biotechnology, vol. 31, no. 9, pp. 822–826, 2013.
[27] C. Kucscu, S. Arslan, R. Singh, J. Thorpe, and M. Adli, “Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease,” Nature Biotechnology, vol. 32, no. 7, pp. 677–683, 2014.
[28] L. S. Qi, M. H. Larson, L. A. Gilbert et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression,” Cell, vol. 152, no. 5, pp. 1173–1183, 2013.
[29] M. H. Larson, L. A. Gilbert, X. Wang, W. A. Lim, J. S. Weissman, and L. S. Qi, “CRISPR interference (CRISPRi) for sequence-specific control of gene expression,” Nature Protocols, vol. 8, no. 11, pp. 2180–2196, 2013.
[30] M. Kampmann, M. A. Horlbeck, Y. Chen et al., “Next-generation libraries for robust RNA interference-based genome-wide screens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 26, pp. E3384–E3391, 2015.
[31] R. Tian, H. Wang, G. D. Gish et al., “Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor,” Proceedings of the National Academy of Sciences, vol. 112, no. 13, pp. E1594–E1603, 2015.
[32] A. Aricò, E. Guadagnin, S. Ferraresso et al., “Platelet-derived growth factors and receptors in canine lymphoma,” *Journal of Comparative Pathology*, vol. 151, no. 4, pp. 322–328, 2014.

[33] J. P. Roose, M. Diehn, M. G. Tomlinson et al., “T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression,” *PLoS Biology*, vol. 1, no. 2, article e53, 2003.

[34] O. Shalem, N. E. Sanjana, and F. Zhang, “High-throughput functional genomics using CRISPR-Cas9,” *Nature Reviews Genetics*, vol. 16, no. 5, pp. 299–311, 2015.

[35] K. P. Lee, C. Taylor, B. Petryniak, L. A. Turka, C. H. June, and C. B. Thompson, “The genomic organization of the CD28 gene: implications for the regulation of CD28 mRNA expression and heterogeneity,” *Journal of Immunology*, vol. 145, no. 1, pp. 344–352, 1990.

[36] X. Jiang, H. Jiang, Z. Shen, and X. Wang, “Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 41, pp. 14782–14787, 2014.